Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 2/20 | 0.72 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.40 |
| ▸ | CCKBR | P32239 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338372 | 0.84 | KCNN4 (0.72) | KCNN4KCNA3LMNACYP1A2CYP3A4 | |
| SCHEMBL41130 | 0.84 | KCNN4 (1.00) | KCNN4KCNA3LMNACYP1A2CYP3A4 | |
| SCHEMBL29499525 | 0.84 | KCNN4 (1.00) | KCNN4KCNA3LMNACYP1A2CYP3A4 | |
| SCHEMBL2403558 | 0.83 | KCNN4 (0.58) | KCNN4KCNA3LMNAMAPTTSHR | |
| SCHEMBL2392374 | 0.82 | KCNN4 (0.69) | KCNN4KCNA3LMNACYP1A2CYP3A4 | |
| SCHEMBL23995584 | 0.81 | KCNN4 (0.68) | KCNN4KCNA3LMNACYP1A2CYP3A4 | |
| SCHEMBL19951665 | 0.81 | KCNN4 (0.68) | KCNN4KCNA3LMNACYP1A2CYP3A4 | |
| SCHEMBL28044107 | 0.81 | KCNN4 (0.68) | KCNN4KCNA3LMNACYP1A2CYP3A4 | |
| SCHEMBL29008837 | 0.77 | KCNN4 (0.62) | KCNN4KCNA3LMNACYP1A2CYP3A4 | |
| SCHEMBL29008817 | 0.77 | KCNN4 (0.58) | KCNN4KCNA3LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017070536-A1 | METHODS AND AGENTS FOR TREATING DISEASES | ANGION BIOMEDICA CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | PGF, VEGFA, MKI67 | KCNN4 4235/4885KCNA3 4627/4885LMNA 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.